Bolt Biotherapeutics, Inc. SEC filings BOLT

Bolt Biotherapeutics, Inc. has 294 filings in SEC EDGAR's recent list, going back to May 7, 2015. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (material agreement, agreement ended, acquisition or sale of assets, unregistered share sale, officer or director change, bylaw or fiscal year change, regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Bolt Biotherapeutics, Inc. SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Apr 28, 2026 —
DEF 14A Proxy statement Apr 28, 2026 Apr 27, 2026
DEF 14A Proxy statement Apr 25, 2025 May 27, 2025
PRE 14A Preliminary proxy statement Apr 16, 2025 May 27, 2025
DEF 14A Proxy statement Apr 15, 2025 May 27, 2025
DEFA14A Additional proxy material May 20, 2024 —
DEFA14A Additional proxy material Apr 26, 2024 —
DEF 14A Proxy statement Apr 26, 2024 Jun 12, 2024
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 Jun 12, 2023
DEFA14A Additional proxy material Apr 28, 2022 —
DEF 14A Proxy statement Apr 28, 2022 Jun 10, 2022

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BOLT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Redwood City, CA
SEC filer status
, Emerging growth company
SEC CIK
1641281
Former names
Bolt Therapeutics, Inc. (until May 7, 2015)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.